Fiscal Estimate - 2003 Session

☑ Original ☑ Updated	Corrected S	Supplemental			
LRB Number 03-0866/1	Introduction Number AB-	648			
Subject					
Exemption for nonprescription drugs					
Fiscal Effect					
AppropriationsRever	ease Existing absorb within agend				
Permissive Mandatory Permis 2. Decrease Costs 4. Decrease Costs 4. Permis Permissive Mandatory Permis	ase Revenue Counties Otsive Mandatory	llage Cities			
Fund Sources Affected Affected Ch. 20 Appropriations					
☑ GPR ☐ FED ☑ PRO ☐ PRS ☐	SEG SEGS 20.835 (4) (g), (gb) and (ge)			
Agency/Prepared By	Authorized Signature	Date			
OOR/ Blair Kruger (608) 266-1310 Dennis Collier (608) 266-5773		11/26/2003			

Fiscal Estimate Narratives DOR 11/26/2003

		Estimate Type	Original
gs ·			
)	s	s	s

Assumptions Used in Arriving at Fiscal Estimate

The bill exempts from tax sales of nonprescription drugs that are for human consumption only, prepackaged for use by consumers, and labeled in accordance with the requirements of state and federal law. The exemption would take effect the first day of the second month after publication.

According to the Kline and Company report, "Nonprescription Drugs USA 2003", nationwide retail sales of nonprescription drugs were about \$16.639 billion in 2002. Also according to Kline, sales of nonprescription drugs are increasing at about 2.5% per year, primarily due to the reclassification of prescription drugs as nonprescription drugs. A table showing the categories of nonprescription drugs on which the fiscal estimate is based is attached.

Assuming the percentage share of nonprescription drugs purchased by Wisconsin consumers is the same as Wisconsin's share of disposable personal income, sales of nonprescription drugs in Wisconsin would be about \$305 million in 2002. Assuming an annual 2.5% increase, Wisconsin sales would be about \$324 million in FY05. Assuming the sales tax exemption under the bill takes effect July 1, 2004 and a 95% compliance rate, sales taxes would decrease about \$15.4 million in FY05 under the bill.

County and stadium sales taxes were about 7.25% of state sales taxes in FY03. Assuming the percentage remains constant, county and stadium sales taxes would decrease by about \$1.1 million in FY05.

Long-Range Fiscal Implications

CATEGORIES OF NONPRESCRIPTION DRUGS

ALLERGY, ASTHMA AND SINUS PRODUCTS

- Allergy relief products
- Asthma medications
- Sinus medications

COUGH AND COLD PREPARATIONS

- Cold medications
- Cough drops and lozenges
- Cough syrups
- Nasal decongestants
- Sore throat remedies
- Topical vapor products

DIGESTIVE PRODUCTS

- Antacids and anti-gas products
- Antidiarrheal preparations
- Antinausea preparations
- Laxatives

FEMININE PRODUCTS

- Feminine deodorants and itching remedies
- Feminine yeast infection remedies
- Personal lubricants

INTERNAL ANALGESICS

- Arthritis pain relievers
- General pain relievers
- Menstrual relief products

NUTRITIONAL PRODUCTS

- Herbal products
- Vitamins and minerals

TOPICAL PRODUCTS

- Acne aids
- Anti-itch products
- Corn, callus and wart removers
- Diaper rash products
- Eye care products
- First aid products
- Fungicidal preparations
- Hair regrowth treatments
- Hemorrhoidal preparations
- Oral care products
- Topical analgesics

OTHER PRODUCTS

- Home diagnostic test kits
- Sleeping aids
- Smoking cessation aids

From Kline and Company, Inc., "Nonprescription Drugs USA 2003", Table 1 (brochure).

Fiscal Estimate Worksheet - 2003 Session

Detailed Estimate of Annual Fiscal Effect

☑ Original ☐ Upda	ted	Corrected	Supplemental		
LRB Number 03-0866/1		Introduction Numb	er AB-648		
Subject	-				
Exemption for nonprescription drugs					
I. One-time Costs or Revenue Impacts	for State	and/or Local Government	t (do not include in		
annualized fiscal effect):			•		
II. Annualized Costs:		Annualized Fisc	cal Impact on funds from:		
		Increased Costs	Decreased Costs		
A. State Costs by Category					
State Operations - Salaries and Fringe	es	\$			
(FTE Position Changes)					
State Operations - Other Costs					
Local Assistance					
Aids to Individuals or Organizations					
TOTAL State Costs by Category		\$	\$		
B. State Costs by Source of Funds					
GPR	<u> </u>				
FED					
PRO/PRS					
SEG/SEG-S					
III. State Revenues - Complete this only when proposal will increase or decrease state revenues (e.g., tax increase, decrease in license fee, ets.)					
		Increased Rev	Decreased Rev		
GPR Taxes		\$	\$-15,400,000		
GPR Earned					
FED					
PRO/PRS (20.835)					
SEG/SEG-S					
TOTAL State Revenues		\$	\$-15,400,000		
NET A	NNUALIZ	ED FISCAL IMPACT			
		<u>State</u>	Local		
NET CHANGE IN COSTS		\$	\$		
NET CHANGE IN REVENUE		\$-15,400,000	\$-1,100,000		
Agency/Prepared By	Au	thorized Signature	Date		
DOR/ Blair Kruger (608) 266-1310	De	nnis Collier (608) 266-5773	11/26/2003		